ArticleEmergency medicine international2026
Prognostic Role of Copeptin, H-FABP, and TTE in Pulmonary Embolism in the Emergency Department.
Article in Emergency medicine international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Role of Copeptin, H-FABP, and TTE in Pulmonary Embolism in the Emergency Department.Emergency medicine international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary embolism (PE) remains a major diagnostic and prognostic challenge in emergency departments due to its heterogeneous clinical presentation and potentially high mortality. Although echocardiography and conventional cardiac biomarkers are commonly used in clinical practice, the additional prognostic value of novel biomarkers such as copeptin and heart-type fatty acid-binding protein (H-FABP) requires further investigation. Methods: This exploratory prospective study (March 2021-September 2022) included adult patients (≥ 18 years) diagnosed with acute PE confirmed by radiological imaging in the emergency department. Patients with chronic/unconfirmed PE, incomplete data, or those referred from external centers were excluded. The primary analysis compared survivors and nonsurvivors at 30 days to evaluate the prognostic value of copeptin, H-FABP, and echocardiographic parameters. Transthoracic echocardiography (TTE) was performed after diagnosis to assess right heart function and pulmonary artery pressure (PAP), right ventricular/left ventricular ratio (RV/LV), right and left ventricular end-diastolic diameters (RV-EDD and LV-EDD), and tricuspid annular plane systolic excursion (TAPSE). Biomarkers (troponin, pro-BNP, D-dimer, copeptin, and H-FABP) were analyzed using standard laboratory assays and enzyme-linked immunosorbent assay (ELISA). The primary outcome was 30-day mortality. Results: A total of 88 patients were analyzed. Although H-FABP and copeptin levels were higher in nonsurvivors, these differences were not statistically significant for predicting 30-day mortality. Echocardiographic parameters-particularly PAP, RV-EDD, and RV/LV-were significantly associated with the severity of right ventricular dysfunction and clinical outcomes ( Conclusions: Although biomarkers were not significant as continuous variables, exploratory categorized analysis based on cut-off values suggested a potential association with mortality. Rapid bedside echocardiography combined with appropriate biomarker testing may improve risk stratification in patients with PE in emergency settings, while larger studies are needed to clarify the role of these biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.